## IN THE SPECIFICATION

Please amend the paragraph beginning on page 19, line 26 as follows:

Figures [[4A-C]] 4A-D. Luciferase activity in HeLa cells after infection with A) AV2.RSVLuc (left panel of Figure 4A) or B) AV2.RSVlucCap5 (right panel of Figure 4A) (100 or 1000 [[ppc]] moi) in the absence or presence of LLnL (40 μM) or doxorubicin (0.5 or 1.0 μM) administration. [[or B)]] C) Luciferase activity after infection with AV2CMVluc [[or]] and AV2CMVluc Cap5 (500 ppc), and LLnL (40 μM), Z-LLL (4 μM), or doxorubicin (0.5 or 1.0 μM) administration. [[C)]] D) and E) Comparison of CMV and RSV promoters in AAV-2 vectors (1000 ppc, left panel of Figure 4C; 100 ppc, right panel of Figure 4C and 100 ppc, respectively) in HeLa cells in the absence or presence of LLnL (40 μM) or doxorubicin (0.5 or 1.0 μM) administration.

Please amend the paragraph beginning on page 20, line 6 as follows:

Figures [[6A-B]] 6A-C. A) Luciferase activity in ferret fibroblasts after infection with AV2CMVluc or AV2CMVluc Cap5 (500 ppc), and administration of LLnL (40<del>, 200 or 400</del> μM), Z-LLL (4 μM), or doxorubicin (1 μM). A) Comparison of AV2CMVluc and AV2CMVlucCap5. [[B)]] B)-C) RLU at 1 and 5 days for AV2CMVluc (left panel of Figure 6B) and AV2CMVlucCap5 (right panel of Figure [[6B]] 6C) in ferret fibroblasts in the absence or presence of LLL or doxorubicin.

Please amend the paragraph beginning on page 20, line 13 as follows:

[[Figure 8]] <u>Figures 8A-C</u>. Luciferase activity in polarized airway epithelial cells at 3 days (<u>Figures 8A and 8B</u>) and 15 days (<u>Figures 8A and 8C</u>) after apical infection with 5 x  $10^9$  <u>AV2CMVluc or AV2CMVlucCap5</u> <u>AV2RSVLue or AV2RSVlueCap5</u> and adminstration of LLnL (40  $\mu$ M) or doxorubicin (1.0 or 5.0  $\mu$ M) or a combination of LLnL (40  $\mu$ M) and

Page 3

doxorubicin (1.0 or 5.0 µM). The upper panel summarizes RLU on days 3 (see middle panel for data from day 3) and 15 (see lower panel for data from day 5).

Please amend the paragraph beginning on page 20, line 17 as follows:

Figures [[9A-B]] 9A-D. Luciferase activity in C57Bl6 mouse lung (Figures 9A and C upper panel in each of Figures 9A-B) or trachea and bronchi (Figures 9B and D lower panel in each of Figures 9A-B) at 2 weeks (Figures 9A-B) [[(A)]] or at 6 weeks (Figures 9C-D) [[(B)]] after infection (via nasal aspiration) with AV2RSVlucCap5 (3 times with 10 μl of 2 x 10<sup>9</sup> particles/μl in 40 μl, for a total of 6 x 10<sup>10</sup> particles) and administration of Z-LLL (200 μM), doxorubicin (200 μM), or a combination of Z-LLL (200 μM) and doxorubicin (200 μM). For each group, n = 12. Lung and trachea with some bronchial tissue was isolated and, after extraction, luciferase activity/total protein in the tissue extraction determined.

Please amend the paragraph beginning on page 20, line 30 as follows:

Figures [[11A-B]] 11A-D. The effects of proteasome inhibitors LLnL (Figures 11A and C left panel of each of Figures 11A-B) and Doxorubicin (Dox) (Figures 11B and D right panel of each of Figures 11A-B) on AV2Luc and AV2/5Luc transduction of immortalized human airway cell lines IB3 (Figures 11A-B Figure 11A) and A549 cells (Figures 11C-D Figure B) were evaluated. Proteasome-modulating agents were co-administered with each rAAV vector (MOI of 500 particles per cell) at the time of infection and transduction was evaluated 24 hours later. Various concentrations of each chemical were evaluated as indicated in each graph. Data represent the mean (+/-SEM) relative luciferase activity experiment (N=4).

Please amend the paragraph beginning on page 21, line 18 as follows:

<u>Figures 13A-B</u> Figure 13. Dox and LLnL provide <u>more than</u> additive induction of rAV2 transduction. Hela cells (A) and A549 cells (B) were infected with rAAV (MOI 500 particles/cell) in the presence of the indicated drug combinations and the expressed transgene was assessed at 24 hours post-infection (Mean +/-SEM, N = 4). Fold induction relative to vehicle-treated rAAV-infected cells is indicated above each bar.